| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
MHC class I H-2Kb molecules and cytotoxic T lymphocytes (CTLs). HSV-gB2 498-505 is an immunodominant epitope derived from HSV glycoprotein B residues 498-505. It is presented by H-2Kb MHC class I molecules and recognized by HSV-1/2-cross-reactive CTLs. The peptide's ability to be recognized by CTLs that cross-react with both HSV-1 and HSV-2 makes it a valuable tool for studying cross-protective immunity.
|
|---|---|
| ln Vitro |
In vitro, HSV-gB2 498-505 is used to stimulate HSV-specific CD8+ T cells. The peptide binds to H-2Kb MHC class I molecules and is recognized by CTLs, leading to T cell activation, proliferation, and cytokine production. It is commonly used in ELISPOT assays, intracellular cytokine staining (ICS), and tetramer staining to quantify antigen-specific T cell responses. The peptide's cross-reactivity with HSV-1 and HSV-2 makes it useful for studying immune responses to both HSV serotypes.
|
| ln Vivo |
In vivo, HSV-gB2 498-505 is used in mouse models to study T cell responses to HSV infection and vaccination. Administration of the peptide induces antigen-specific CD8+ T cell responses in H-2Kb mice. The peptide is used in adoptive transfer experiments to study T cell expansion, differentiation, and memory formation following HSV infection or immunization. It is also used in viral challenge models to evaluate protective immunity against HSV-1 and HSV-2.
|
| Enzyme Assay |
In vitro peptide-MHC binding assays for HSV-gB2 498-505 measure the peptide's affinity for H-2Kb MHC class I molecules. The assay uses purified H-2Kb molecules (or cell lines expressing H-2Kb) and fluorescently labeled reference peptides. Varying concentrations of HSV-gB2 498-505 are incubated with H-2Kb molecules and beta2-microglobulin. After equilibration, bound peptide is detected by ELISA or fluorescence polarization. The peptide's binding affinity (IC50 or Kd) is calculated from competition curves. Alternatively, RMA-S cell lines (which are TAP-deficient and load exogenous peptides onto MHC) are used to measure peptide-MHC stabilization by flow cytometry.
|
| Cell Assay |
In vitro T cell activation assays using HSV-gB2 498-505 are performed with splenocytes or purified CD8+ T cells from HSV-immune or TCR transgenic mice. Cells are cultured with varying concentrations of the peptide (typically 0.001-10 microg/mL) for 2-6 hours in the presence of brefeldin A or monensin for cytokine detection. T cell activation is measured by intracellular cytokine staining (IFN-gamma, TNF-alpha, IL-2) followed by flow cytometry. Alternatively, ELISPOT assays are used to enumerate peptide-specific IFN-gamma-producing cells. CFSE dilution assays measure peptide-induced T cell proliferation after 3-5 days of culture.
|
| Animal Protocol |
In vivo mouse studies with HSV-gB2 498-505 are conducted in H-2Kb mice (e.g., C57BL/6). For immunization, mice receive the peptide (typically 10-100 microg) emulsified in adjuvant (e.g., CFA, IFA, or CpG) via subcutaneous or intraperitoneal injection. For T cell tracking, HSV-specific T cells are labeled with CFSE or a cell tracer and adoptively transferred into recipient mice. Mice are then immunized with peptide or infected with HSV-1 or HSV-2. Spleen and lymph nodes are harvested for flow cytometric analysis of T cell expansion, activation, and differentiation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of HSV-gB2 498-505 are characteristic of peptide antigens. With a molecular weight of 922.04, the peptide is soluble in aqueous solutions. It is typically stored as a powder at -20degC. As a research peptide, pharmacokinetic studies are not typically performed as it is used as an antigen rather than a therapeutic agent. The peptide's stability and immunogenicity are the primary considerations in experimental design.
|
| Toxicity/Toxicokinetics |
Toxicological data for HSV-gB2 498-505 are not extensively documented as the peptide is used for research purposes only and not for therapeutic applications. As a short peptide antigen, it is generally well-tolerated in mouse studies at immunogenic doses. Standard safety precautions for handling peptides apply. The compound is intended for research use only and not for human therapeutic use. No significant toxicity has been reported in the literature for this research peptide.
|
| References | |
| Additional Infomation |
HSV-gB2 498-505 is a research-grade synthetic peptide used in immunology and virology research. It is an immunodominant epitope from HSV glycoprotein B residues 498-505. The peptide acts as an H-2Kb-restricted and HSV-1/2-cross-reactive CTL recognition epitope. It is used to study CD8+ T cell responses against HSV infection, vaccine development, and cross-protective immunity between HSV-1 and HSV-2. The peptide's molecular weight is 922.04. Not approved for clinical use.
|
| Molecular Formula |
C41H67N11O13
|
|---|---|
| Molecular Weight |
922.036589860916
|
| Exact Mass |
921.491
|
| CAS # |
149997-91-1
|
| PubChem CID |
5478856
|
| Appearance |
White to off-white solid powder
|
| LogP |
-4.4
|
| Hydrogen Bond Donor Count |
14
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
30
|
| Heavy Atom Count |
65
|
| Complexity |
1640
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(=O)O)CC(C)C)(NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CO)CC1C=CC=CC=1
|
| InChi Key |
UBVOHDHFHIMSCO-YWZBYMRGSA-N
|
| InChi Code |
InChI=1S/C41H67N11O13/c1-6-22(4)32(52-38(62)30(20-54)51-34(58)25(42)19-53)39(63)48-27(14-15-31(55)56)36(60)49-28(18-24-11-8-7-9-12-24)37(61)46-23(5)33(57)47-26(13-10-16-45-41(43)44)35(59)50-29(40(64)65)17-21(2)3/h7-9,11-12,21-23,25-30,32,53-54H,6,10,13-20,42H2,1-5H3,(H,46,61)(H,47,57)(H,48,63)(H,49,60)(H,50,59)(H,51,58)(H,52,62)(H,55,56)(H,64,65)(H4,43,44,45)/t22-,23-,25-,26-,27-,28-,29-,30-,32-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~5.88 mg/mL (~6.38 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0846 mL | 5.4228 mL | 10.8455 mL | |
| 5 mM | 0.2169 mL | 1.0846 mL | 2.1691 mL | |
| 10 mM | 0.1085 mL | 0.5423 mL | 1.0846 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
